Med-IQ Logo
Get CME/CE

Course Listings: Oncology

All Results (15)
Format: Live Events (0) Online Activities (15)

Case Simulations in Optimizing Treatment Plans for Metastatic Pancreatic Cancer

View Course

Format: Simulation

    Maximum Credits:
  • 0.75 AMA PRA Category 1 Credit(s)

Course Description: In this video-enhanced, CME-certified, case-based simulation, clinicians are challenged to select appropriate therapies for two patients with metastatic pancreatic adenocarcinoma. Throughout the activity, clinicians must consider multiple clinical factors including patient- and disease-related characteristics, patient preferences, and the latest evidence to…More


Improving Multiple Myeloma Care in a Rapidly Evolving Field

View Course

Format: Webcast

    Maximum Credits:
  • 1.0 AMA PRA Category 1 Credit(s)

Course Description: This CME Webcast explores clinical management strategies for multiple myeloma. Experts in the field use patient cases to discuss current clinical evidence and treatment guidelines for newly diagnosed and relapsed/refractory disease, with a focus on patient-, disease-, and treatment-related factors that guide therapeutic decisions.


Addressing Barriers to Advanced NSCLC Care

View Resource

Format: Audioconference

Course Description: In these free, personalized audioconferences, clinicians speak with nationally renowned experts in advanced NSCLC. During this live conversation, participants identify barriers to optimal advanced NSCLC treatment in their own practices and receive guidance on developing strategies to overcome them. The purpose of this initiative is to identify gaps, barriers,…More

Note: This material is not CME certified and, therefore, does not offer any CME/CE credit.


Key Concepts in the Ever-Evolving Therapeutic Landscape of Advanced HER2-Positive and Triple-Negative Breast Cancer

View Course

Format: E-publication

    Maximum Credits:
  • 0.75 AMA PRA Category 1 Credit(s)

Course Description: This interactive publication examines current evidence and guideline recommendations for the treatment of HER2-positive and triple-negative breast cancer. It also features audio clips of expert faculty perspectives regarding key findings and clinical evidence from the latest immunotherapy trials to help oncologists apply these data when developing…More


Recognizing Gaucher’s Disease in the Hematology Clinic

View Course

Format: Presentation Points

    Maximum Credits:
  • 0.5 AMA PRA Category 1 Credit(s)

Course Description: This transcript-based, CME-certified Presentation Points publication summarizes a satellite symposium presented by Pramod K. Mistry, MD, PhD, FRCP, and Neal J. Weinreb, MD, FACP, nationally renowned experts in Gaucher’s disease (GD) type 1. Faculty present strategies for recognizing symptoms early in the disease course and discuss the implications of…More


Case Simulations in Metastatic Melanoma: Navigating Complex Treatment Decisions

View Course

Format: Simulation

    Maximum Credits:
  • 1.0 AMA PRA Category 1 Credit(s)

Course Description: In these video-enhanced, CME-certified, case-based simulations, clinicians are challenged to select first- and subsequent-line treatment regimens for two fictional patients with stage IV melanoma. Throughout the activity, clinicians must consider patient- and tumor-related characteristics, patient preferences, and contemporary evidence to make appropriate…More


Helping Clinicians Navigate the Complexities of Advanced NSCLC Treatment

View Course

Format: Presentation Points

    Maximum Credits:
  • 1.0 AMA PRA Category 1 Credit(s)

Course Description: This CME-certified Presentation Points is a slightly abridged transcript of a presentation given by Drs. H Jack West and Corey Langer on the treatment for advanced non–small cell lung cancer (NSCLC). These experts discussed biomarker testing to inform optimal treatment decisions, as well as the latest scientific evidence on the role of anti-angiogenic agents…More


Managing CLL With Oral Agents

View Course

Format: Webinar

    Maximum Credits:
  • 1.0 AMA PRA Category 1 Credit(s)
  • 1.0 California Board of Registered Nursing (CBRN)

Course Description: This activity brings together two nationally recognized experts to discuss the practical considerations of managing CLL with oral agents. It explores the benefits and challenges of oral CLL therapies, discusses strategies for monitoring and managing adverse events, and addresses barriers to adherence.


Sequencing Treatment for Metastatic Castration-Resistant Prostate Cancer: How to Match Patients to the Right Therapy

View Course

Format: E-publication

    Maximum Credits:
  • 1.0 AMA PRA Category 1 Credit(s)

Course Description: This interactive, audio-enhanced online publication discusses available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in both the first- and second-line settings. Additionally, case studies from a national survey of oncologists and urologists are presented to illuminate common practice challenges. Expert faculty…More


Integrating Advances and Optimizing Contemporary Strategies in Renal Cell Carcinoma

View Course

Format: E-publication

    Maximum Credits:
  • 0.5 AMA PRA Category 1 Credit(s)

Course Description: This CME-certified publication reviews the treatment options for patients with metastatic renal cell carcinoma (mRCC), discusses the latest clinical evidence for available therapeutic options, and explores the patient- and disease-related factors that should be considered when planning mRCC treatment.


Prevention of Chemotherapy-Induced Neutropenia in Breast Cancer: A Focus on Colony-Stimulating Factors

View Course

Format: Med-IQ Express

    Maximum Credits:
  • 0.25 AMA PRA Category 1 Credit(s)

Course Description: This activity presents the latest guideline recommendations for identifying patients with breast cancer who have a risk of developing chemotherapy-induced neutropenia. It also provides guideline-based strategies for initiating preventive treatment, with a special focus on evidence associated with available and emerging granulocyte colony-stimulating factors.


Hope on the Horizon? The Science Behind New and Emerging Therapeutic Strategies for Pancreatic Cancer

View Course

Format: Audiocast

    Maximum Credits:
  • 0.5 AMA PRA Category 1 Credit(s)

Course Description: This Web-based CME audiocast presents the latest evidence on the role of the tumor microenvironment in pancreatic cancer biology and its contribution to tumor progression and therapeutic response. Additionally, this activity explores emerging treatment strategies for advanced pancreatic cancer, including stromal-modifying agents, novel cytotoxic agents,…More


Prolonging Survival in Patients With Metastatic Colorectal Cancer Using Novel VEGF-Directed, Antiangiogenic Agents

View Course

Format: Med-IQ Express

    Maximum Credits:
  • 0.25 AMA PRA Category 1 Credit(s)

Course Description: This 15-minute publication begins with a brief video in which a clinical expert reviews the use of antiangiogenic agents in patients with progressive metastatic colorectal cancer (mCRC). The publication then presents key guideline recommendations and a focused discussion on pivotal trials of the 4 main agents used to prolong survival in patients with mCRC.


Managing CLL With Targeted Oral Agents: Educating and Empowering Patients to Improve Adherence

View Course

Format: E-publication

    Maximum Credits:
  • 0.5 AMA PRA Category 1 Credit(s)

Course Description: This CME publication addresses the practical considerations of using oral agents in the treatment of chronic lymphocytic leukemia. It reviews strategies for managing adverse events, discusses reasons for medication nonadherence, and offers tips for engaging patients and improving adherence to oral agents.


Advances in Pancreatic Cancer Treatment: Options When First-Line Therapy Fails

View Course

Format: E-publication

    Maximum Credits:
  • 0.75 AMA PRA Category 1 Credit(s)

Course Description: This Web-based CME publication presents contemporary evidence on the use of available treatments in patients with advanced metastatic pancreatic cancer. The biologic importance and potential therapeutic implications of the stromal microenvironment is also explored along with an update on several agents under development for pancreatic cancer.